- Home
- INCR vs CRBP Comparison
INCR vs CRBP Comparison
Compare INCR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- CRBP
- Stock Information
- Founded
- INCR 1994
- CRBP 2009
- Country
- INCR Israel
- CRBP United States
- Employees
- INCR N/A
- CRBP N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- CRBP Health Care
- Exchange
- INCR Nasdaq
- CRBP Nasdaq
- Market Cap
- INCR 84.5M
- CRBP 96.5M
- IPO Year
- INCR N/A
- CRBP N/A
- Fundamental
- Price
- INCR $1.51
- CRBP $8.52
- Analyst Decision
- INCR
- CRBP Strong Buy
- Analyst Count
- INCR 0
- CRBP 10
- Target Price
- INCR N/A
- CRBP $53.56
- AVG Volume (30 Days)
- INCR 28.2K
- CRBP 214.6K
- Earning Date
- INCR 08-15-2025
- CRBP 08-05-2025
- Dividend Yield
- INCR N/A
- CRBP N/A
- EPS Growth
- INCR N/A
- CRBP N/A
- EPS
- INCR N/A
- CRBP N/A
- Revenue
- INCR $65,575,323.00
- CRBP N/A
- Revenue This Year
- INCR $69.54
- CRBP N/A
- Revenue Next Year
- INCR $41.75
- CRBP $270.04
- P/E Ratio
- INCR N/A
- CRBP N/A
- Revenue Growth
- INCR N/A
- CRBP N/A
- 52 Week Low
- INCR $1.17
- CRBP $4.64
- 52 Week High
- INCR $2.62
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- INCR 46.22
- CRBP 57.40
- Support Level
- INCR $1.48
- CRBP $8.01
- Resistance Level
- INCR $1.64
- CRBP $8.85
- Average True Range (ATR)
- INCR 0.05
- CRBP 0.48
- MACD
- INCR -0.00
- CRBP 0.08
- Stochastic Oscillator
- INCR 30.81
- CRBP 90.02
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.